-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
January 16 (Xinhua Huayi) Japanese researchers said on the 16th, an eye disease patient last year transplanted an allogeneic induced pluripotent stem cell (iPS cell) cultured retinal cells, the emergence of retinal edema.
this is the first complication since the clinical study was conducted.
iPS cells are stem cells grown by "reprogramming" mature somatic cells, with similar differentiation potential to embryonic stem cells.
compared with the use of the patient's own iPS cells, the cost and time required to grow a tissue cell with an allogeneic iPS cell is greatly reduced, so the relevant research in the medical community has attracted much attention.
last March, researchers at the Japan Institute of Science and Chemistry and others announced the world's first transplant of their kind, transplanting retinal cells grown from allogeneic iPS cells into the right eye of a 60-year-old male with age-related macular degeneration.
since then, they performed similar transplants on four elderly macular degeneration patients.
, however, the researchers admitted on the 16th of this month, one of the 70-year-old male patients had retinal edema, although no urgent treatment is required, but also no hope of improvement, so they performed a retinal pre-membrane removal surgery for the patient on the 15th. Takahashi, program leader at the Institute of
AndEring chemistry, said there can be no denying a causal link between the condition and the use of iPS cells, but it will not affect progress.
.